Tempus is Eric Lefkofsky’s latest venture. A health-tech startup whose aim is to facilitate cancer treatment via Big Data analytics by taking advantage of the recent human genome sequencing, science and technology advances, it has secured around $130 million in venture capital as well as a spot among Chicago’s top ten health techs.
Tempus has recently paired with Precision HealthAI, and the two data services companies established a collaboration with CancerLinQ LLC. By working together, they will accelerate development and delivery of high-quality, de-identified clinical databases. This, in turn, will be linked with CancerLinQ, and thus make the data available to oncologist subscribers, partners and the broader cancer community.
In more detail, through the collaboration, Tempus and Precision HealthAI will organize data into high-quality datasets, which will be accessible through the core CancerLinQ quality improvement platform and CancerLinQ Discovery a service that provides access to high-quality, de-identified datasets for non-profit organizations, health care providers, academic researchers, and government agencies. These curated datasets will then be made available to industry partners for enhanced applicability. The aim is to use them in order to establish targeted therapies, more efficient clinical trials and data-driven analyses, all of which would ideally yield therapy options with the greatest patient benefit.
According to Clifford Hudis, MD, FACP, FASCO, CEO of ASCO and Chairman of the CancerLinQ Board of Governors, “Tempus and Precision HealthAI bring first-rate technical capacity that complements CancerLinQ’s existing strengths.” He continues with, “They share our vision for improving patient care and have the right combination of experience and commitment to innovation to help us provide useful information, faster, to subscribing practices and the entire cancer community.”
Lefkofsky describes Tempus as a platform that “helps usher in an era of precision medicine, empowering physicians with the tools and information they need to improve patient outcomes.” “Building on the vast network that CancerLinQ has established, our team will apply sophisticated technology tools to this large body of clinical and molecular data to help power cutting-edge research and produce actionable clinical insights,” Lefkofsky elaborates.
Romesh Wadhwani, PhD, Chairman of Precision HealthAI comments that “We are developing an innovative AI platform for the management, delivery and use of clinical data. Our experienced team of health care data and technology professionals focus on developing artificial Intelligence and machine learning-driven solutions for a range of oncology stakeholders.” He adds that “Applying our technology solution to de-identified CancerLinQ data will help the broader community to accelerate research and the development and administration of new therapies.”
The license agreement will allow CancerLinQ to maintain its non-profit status as well as its responsibility for data integration and providing a platform of meaningful tools and reports to participating oncologists and oncology care sites. On the other hand, Tempus and Precision HealthAI will work on further structuring this dataset for the benefit of patients. CancerLinQ is present in more than 100 oncology practices, where they account for more than 2,000 medical oncologists and have contributed more than a million cancer patient records in the database. They are present in 40 states, with the District of Columbia as its newest participant. The agreement with Tempus and Precision HealthAI is part of a broad group of collaborations that CancerLinQ LLC has established with government agencies, medical specialty societies, and life sciences companies.
CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick is optimistic about the agreement, as he believes that the company’s commitment to the physicians and the cancer patients they treat is the strongest it has ever been, and that “this collaboration will allow us to deliver cutting-edge clinical tools and enhanced benefits to the cancer centers participating in CancerLinQ.” According to him “As a result of the technical and financial contributions of Tempus and Precision HealthAI, CancerLinQ aims to accelerate the pace of new quality improvement services to its subscribers.”
Tempus is one of several ventures Lefkofsky has founded. These are Groupon, Echo Global Logistics, InnerWorkings, Lightbank, Uptake Technologies, and Mediaocean. Lefkofsky is the author of Accelerated Disruption: Understanding the True Speed of Innovation. He has also held teaching positions at the Kellstadt Graduate School of Business at DePaul University as well as at Northwestern University’s Kellogg School of Management. He is currently an adjunct professor at the University of Chicago’s Booth School of Business.
Lefkofsky’s philanthropic endeavors include the Lefkofsky Family Foundation that he founded in 2006 together with his wife. The foundation’s primary aim is the advancement of high-impact initiatives in education, fundamental human rights, medicine, art and culture that enhance lives in the communities that are served. The two are also members of The Giving Pledge. Lefkofsky is also on the board of trustees of the Lurie’s Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He is also the Chairman of the Chicago-based Board of Trustees of the Steppenwolf Theatre Company.
For more information on Eric Lefkofsky, please visit lefkofsky.com, LinkedIn: ericlefkofsky, Twitter: @lefkofsky or Facebook: @eplefkofsky. For more information on Tempus, please visit tempus.com, Facebook: @TempusLabs and Twitter: @TempusLabs. For more information on participation or partnering with CancerLinQ, please visit CancerLinQ.org.